Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
長谷川京子、ジュエリー級の輝き&黒ドレスから“ポロリ”
加藤浩次、21歳当時バイトのバーで会った大物歌手との再会に感動「こうちゃん」と呼んでくれて
大仁田厚もコンプラに屈した…「今年からやめたんだ、ひどいから」伝統芸を自ら封印
【ソフトバンク】全治4カ月の柳田悠岐、ファーム施設に姿見せず「1週間ぐらい自宅療養」関係者
【ソフトバンク】ロバート秋山&アルピー平子「体格ブラザーズ」始球式「福岡でもファンがいる」
玉置浩二が太陽の塔の眼下で「愛と平和」掲げたコンサートツアー完遂
NMB48川上千尋「ミャクミャクと阪神を盛り上げていきたい」阪神連敗ストップ才木浩人に感謝
「omoinotake」ヒット中「幾億光年」チェ・ジュンソンとコラボ「すごく気持ち良かった」
【巨人】菅野智之、12球団本拠地勝利達成「新しい自分を磨く」開幕から無傷5連勝に誇りと自信
卒業発表のモー娘。石田亜佑美に竹内朱莉「卒業がワクワクする人は初めて」佐々木莉佳子ら言及
柏原崇(45)現在を調べてみた結果、相変わらずかっこよすぎた!
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
浜崎あゆみ、子供の写真公開に疑いの声止まず「よそのお宅の子供?」
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
大谷翔平被弾投手が悪態ついて退場処分!次打者フリーマンと対戦中に判定巡り塁審と口論
YouTuberジュキヤの動画企画が大炎上「普通に痴漢」「気持ち悪すぎ」
千原せいじのシエラレオネ巡る発言 NPO代表理事が公式謝罪忠告「最悪、国家間の問題に発展」
大谷翔平10試合ぶり14号 シティフィールド初アーチ、26球場目は自らの日本人記録更新
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
大谷に被弾→次打者判定で審判と口論→退場→「チーム、自分も最悪」→戦力外
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
柏原崇(45)現在を調べてみた結果、相変わらずかっこよすぎた!
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
TikTokを賑わす「フエラムネごめんなサイダー味」がセブンイレブンで再販!じゅるるマスカットも買うなら今!
小倉優子、不自然な“二重ライン”にネット騒然「やっぱり整形?」
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
大原櫻子、ガーシー暴露後初のSNS投稿に賛否の声「イメージ最悪になった」
長谷川京子、ジュエリー級の輝き&黒ドレスから“ポロリ”
加藤浩次、21歳当時バイトのバーで会った大物歌手との再会に感動「こうちゃん」と呼んでくれて
大仁田厚もコンプラに屈した…「今年からやめたんだ、ひどいから」伝統芸を自ら封印
【ソフトバンク】全治4カ月の柳田悠岐、ファーム施設に姿見せず「1週間ぐらい自宅療養」関係者
【ソフトバンク】ロバート秋山&アルピー平子「体格ブラザーズ」始球式「福岡でもファンがいる」
玉置浩二が太陽の塔の眼下で「愛と平和」掲げたコンサートツアー完遂
NMB48川上千尋「ミャクミャクと阪神を盛り上げていきたい」阪神連敗ストップ才木浩人に感謝
「omoinotake」ヒット中「幾億光年」チェ・ジュンソンとコラボ「すごく気持ち良かった」
【巨人】菅野智之、12球団本拠地勝利達成「新しい自分を磨く」開幕から無傷5連勝に誇りと自信
卒業発表のモー娘。石田亜佑美に竹内朱莉「卒業がワクワクする人は初めて」佐々木莉佳子ら言及